![](https://webarchive.library.unt.edu/web/20090509202635im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20090509202635im_/http://www.cancer.gov/images/spacer.gif)
TLR9 agonist IMO-2055 A synthetic oligonucleotide containing unmethylated CpG dinucleotides with potential immunopotentiating activity. Mimicking unmethylated CpG sequences in bacterial DNA, TLR9 agonist IMO-2055 binds to and activates intracellular Toll-like receptors (TLR) 9 in monocytes/macrophages, plasmacytoid dendritic cells (DCs) and B cells, initiating immune signaling pathways and activating B cells and DCs and inducing T-helper cell cytokine production. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/web/20090509202635im_/http://www.cancer.gov/images/spacer.gif)
Code name: | ![](https://webarchive.library.unt.edu/web/20090509202635im_/http://www.cancer.gov/images/spacer.gif) | IMO-2055 | | ![](https://webarchive.library.unt.edu/web/20090509202635im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20090509202635im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20090509202635im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20090509202635im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20090509202635im_/http://www.cancer.gov/images/spacer.gif) |